相关实验视频

Updated: Jun 9, 2025

Modeling an Enzyme Active Site using Molecular Visualization Freeware

Modeling an Enzyme Active Site using Molecular Visualization Freeware

Published on: December 25, 2021

基于药的3D-QSAR建模,虚拟查,对接,分子动力学和生物评估研究用于识别潜在的α-葡萄糖酶抑制剂

Unnati Kushavah^1,2, Pinaki Prasad Mahapatra^1,2, Shakil Ahmed^1,2

¹Biochemistry and Structural Biology Division, CSIR-Central Drug Research Institute, Sector 10, Jankipuram Extension, Sitapur Road, Lucknow, 226031, India.

Journal of molecular modeling

|October 30, 2024

概括

新的支架被确定为2型糖尿病管理的潜在α-葡萄糖酶抑制剂. 这项研究利用了药模拟,分子对接和生物评估,以发现针对高血糖的新治疗剂.

科学领域:

药用化学医学化学
计算化学计算化学
药理学药理学是指药理学的学科.

背景情况:

阿尔法-葡萄糖酶是管理2型糖尿病高血糖症的关键治疗标.
识别新型抑制剂对于开发有效的抗糖尿病治疗至关重要.

研究的目的:

使用计算方法识别新的α-葡萄糖酶抑制剂.
通过分子对接和生物评估验证潜在的抑制剂.

主要方法:

开发并验证了一个3D-QSAR药模型,使用51个xanthon支架.
使用施罗丁格软件进行虚拟选和分子对接.
对所选化合物进行分子动力学分析和生物分析.

主要成果:

建立了一个强大的3D-QSAR模型,具有高统计意义 (Q2=0.66,R2=0.95).
虚拟查发现了新的潜在的α-葡萄糖酶抑制剂.
四种化合物在生物测试中表现出显著的抑制活性.

结论:

该研究成功地确定了新型支架作为潜在的α-葡萄糖酶抑制剂.
计算方法与生物评估相结合,对于药物发现是有效的.
这些发现为2型糖尿病治疗提供了有希望的候选人.

关键词:

3D-QSAR 是一个3D-QSAR.阿尔法-葡萄糖化剂酶抑制可以抑制酶.分子对接是分子对接.分子动力学分子动力学

更多相关视频

Screening Traditional Chinese Medicine Compounds for Inhibiting UCHL3 Activity Based on Molecular Docking and Deubiquitinating Enzyme Probe Technology

Screening Traditional Chinese Medicine Compounds for Inhibiting UCHL3 Activity Based on Molecular Docking and Deubiquitinating Enzyme Probe Technology

Published on: November 22, 2024

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

相关概念视频

Structure-Activity Relationships and Drug Design

Structure-Activity Relationships and Drug Design

Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...

Drug Discovery: Overview

Drug Discovery: Overview

Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...